BRIEF published on 12/11/2024 at 07:34, 1 year 5 months ago Evotec SE et Novo Nordisk lancent les projets LAB eN² pour la découverte de médicaments Evotec SE Découverte De Médicaments Novo Nordisk LAB EN² Maladies Cardiométaboliques
PRESS RELEASE published on 12/11/2024 at 07:29, 1 year 5 months ago Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk Evotec SE announces selection of first projects for LAB eN² drug discovery accelerator with Novo Nordisk, focusing on cardiometabolic diseases from academic institutions Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
BRIEF published on 11/29/2024 at 07:36, 1 year 5 months ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
BRIEF published on 11/29/2024 at 07:36, 1 year 5 months ago Evotec annonce le départ de son directeur opérationnel et une restructuration interne Changement De Direction Evotec Médicaments Départ Du COO Restructuration Interne
PRESS RELEASE published on 11/29/2024 at 07:31, 1 year 5 months ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 1 year 5 months ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
BRIEF published on 11/22/2024 at 17:00, 1 year 5 months ago Evotec SE commente le retrait de l'offre d'Halozyme Evotec SE Valeur Actionnariale Proposition D'acquisition Thérapeutique Halozyme Offre Sans Engagement
PRESS RELEASE published on 11/22/2024 at 16:55, 1 year 5 months ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 year 5 months ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
BRIEF published on 11/14/2024 at 22:56, 1 year 5 months ago Evotec SE répond à l'intérêt d'Halozyme Evotec SE Reprendre Thérapeutique Halozyme Manifestation D'intérêt 11 EUR Par Action
Published on 05/13/2026 at 00:00, 2 hours 15 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 2 hours 40 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 4 hours 20 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 4 hours 33 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 11 hours 45 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 23:47, 2 hours 27 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 3 hours 49 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 5 hours 53 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 6 hours 39 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 6 hours 39 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:15, 8 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 8 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 8 hours 5 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 8 hours 5 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 8 hours 25 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
